RESUMO
The sequencing of the human genome has already had an enormous impact on medicine, particularly with single-gene changes that predispose to a serious disease such as cystic fibrosis or the overexpression of Her2 in about one-third of breast cancers. Genetic technology has led to some very important therapeutic innovations, including the use of imatinib mesylate (Gleevec) in BCR-ABL chronic myeloid leukemia and of trastuzumab (Herceptin) in Her2-positive breast cancer, but the much anticipated explosion of new effective treatments has been more modest than expected.
Assuntos
Desenho de Fármacos , Indústria Farmacêutica/tendências , Genoma Humano , Genômica , Farmacogenética/tendências , Farmacologia Clínica/tendências , Fenômenos Fisiológicos/efeitos dos fármacos , Fisiologia/tendências , Animais , Pesquisa Biomédica/tendências , Ensaios Clínicos como Assunto/tendências , Humanos , Seleção de Pacientes , Fenômenos Fisiológicos/genética , Projetos de Pesquisa/tendências , Biologia de Sistemas/tendências , Recursos HumanosRESUMO
Arachidonic acid was converted to a series of hydroxyeicosatetraenoic acids (HETEs) by mixed human inflammatory cells following stimulation with the calcium ionophore A23187. HETEs were purified by a simple one-step extraction procedure followed by HPLC. The HPLC was coupled to a Finnigan quadrupole mass spectrometer using the now commercially available thermospray liquid chromatography-mass spectrometry interface. The HPLC eluant was monitored 'on line' by the mass spectrometer. Soft ionisation occurs, generating intense molecular ion species in the negative ion mode (M - H-:m/z 319) for each of the isomeric HETEs. The (M + H+ - H2O) ion at m/z 303 is the major species in the positive ion spectra of HETEs. Mass spectra were obtained on-line post-HPLC for HETEs formed by the human cells, and the HPLC-MS profile compared with that obtained from standards; species corresponding to the 11-, 9- and 5-HETEs were observed.
Assuntos
Ácidos Hidroxieicosatetraenoicos/metabolismo , Inflamação/metabolismo , Ácido Araquidônico , Ácidos Araquidônicos/metabolismo , Líquido Ascítico/metabolismo , Calcimicina/farmacologia , Cromatografia Líquida de Alta Pressão , Ciclosporinas/farmacologia , Cromatografia Gasosa-Espectrometria de Massas , HumanosRESUMO
Thromboxane (TX) B2, 2,3-dinor-TXB2, 11-dehydro-TXB2, 6-oxoprostaglandin (PG)F1 alpha and 2,3-dinor-6-oxo-PGF1 alpha were measured in 24 h urine samples obtained from 30 apparently healthy chronic cigarette smokers and 37 closely matched non-smoking control subjects. Samples were analysed using a newly developed assay based on immunoaffinity chromatography and capillary column gas chromatography/electron capture negative ion chemical ionisation mass spectrometry. There were significant and comparable increases in the excretion rates of both 2,3-dinor-TXB2 and 11-dehydro-TXB2 in the smoking compared with the non-smoking group (2P less than 0.001). Excretion rates of 2,3-dinor-TXB2 were 418 +/- 35 and 265 +/- 26 pg/mg creatinine in the two groups, respectively. 11-Dehydro-TXB2 excretion rates were 440 +/- 54 and 221 +/- 18 pg/mg creatinine, respectively (mean +/- S.E.). There were significant (2P less than 0.05) positive correlations between average reported cigarette consumption and excretion of both thromboxane metabolites. There were small but significant (2P less than 0.02) increases in the excretion rates of both 6-oxo-PGF1 alpha and 2,3-dinor-6-oxo-PGF1 alpha in the smoking compared with the non-smoking group. There was no significant difference in the rates of excretion of TXB2 in the two groups. The effects of acute cigarette smoke exposure (five cigarettes in 2 h) was also studied in four normally non-smoking healthy volunteers. There was no significant change in the excretion rate of any of the eicosanoids measured during control and smoking periods (at least 2 weeks apart), indicating that increased TXA2 biosynthesis in chronic smokers is unlikely to be a consequence of acute platelet activation.
Assuntos
6-Cetoprostaglandina F1 alfa/urina , Fumar/urina , Tromboxano B2/urina , 6-Cetoprostaglandina F1 alfa/isolamento & purificação , Adulto , Cromatografia de Afinidade , Deutério , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Masculino , Radioimunoensaio , Técnica de Diluição de Radioisótopos , Valores de Referência , Tromboxano B2/análogos & derivados , Tromboxano B2/isolamento & purificaçãoRESUMO
There is now compelling evidence that macrophages bind IgE, and are involved in several IgE-dependent responses. The CD23 antigen mediates a mitogenic response in "primed" B-lymphocytes, although its expression is not confined to B cells, and CD23 is inducably expressed in many cells including macrophages. CD23 is also known to bind IgE, a property that leads to inhibition of the mitogenic response in B cells. In the present review, the possibility that CD23 mediates IgE-dependent responses in macrophages has been re-examined, and it is proposed that the functional receptor for IgE on macrophages may be quite separate from the CD23 antigen.
Assuntos
Antígenos de Diferenciação de Linfócitos B/fisiologia , Ativação de Macrófagos , Macrófagos/fisiologia , Receptores Fc/fisiologia , Linfócitos B/fisiologia , Linhagem Celular , Humanos , Técnicas In Vitro , Interleucina-4/fisiologia , Receptores de IgE , Receptores Imunológicos/fisiologia , Transdução de Sinais , Tromboxano B2/metabolismoRESUMO
The decline in blood pressure (BP) in essential hypertensives following hospitalization may result from: 1) regression toward the mean; 2) reduction of anxiety as patients habituate to a new environment; 3) the placebo effect of medication; and 4) an independent effect of hospitalization itself. A randomized crossover study of 12 essential hypertensives demonstrated a fall in supine blood pressure from 165.0/97.9 +/- 2.3/1.1 mm Hg to 154.3/89.6 +/- 2.7/1.1 mm Hg (p less than 0.005) due to hospitalization. A similar reduction in BP from 164.9/99.5 +/- 8.4/4.1 mm Hg to 151.9/93.4 +/- 4.5/1.9 mm Hg (p less than 0.005) resulted from regression toward the mean and habituation during the study period. Urinary catecholamines fell from 68.7 +/- 5.0 to 55.1 +/- 4.3 micrograms/g creatinine/24 hours (p less than 0.05) due to hospitalization and from 56.1 +/- 5.4 to 49.7 +/- 4.3 micrograms/g creatinine/24 hours (p less than 0.05) with time. Although placebo therapy tended to reduce BP, it failed to do so significantly. When expressed as a percentage of the individual's overall mean, urinary catecholamine excretion fell from 110.5% +/- 3.7% to 89.5% +/- 3.7% (p less than 0.001) during hospitalization and from 105.8% +/- 3.9% to 94.2% +/- 3.9% (p less than 0.05) during the outpatient period. Blood pressure and sympathetic activity rapidly returned to prehospitalization values on discharge. These factors may confound the analysis of drug effects on BP and sympathetic activity in essential hypertensives following admission to hospital.
Assuntos
Pressão Sanguínea , Hospitalização , Hipertensão/psicologia , Placebos/uso terapêutico , Sistema Nervoso Simpático/fisiopatologia , Adulto , Idoso , Catecolaminas/urina , Feminino , Frequência Cardíaca , Humanos , Hipertensão/terapia , Masculino , Pessoa de Meia-Idade , Norepinefrina , Renina/sangueRESUMO
Many antihypertensive drugs have adverse effects on glycemic control when they are used in diabetic patients. This was noted for thiazide diuretics in 1960, and the mechanism of the effects remains uncertain. Indirect evidence suggests that changes in the serum potassium are at least contributory, although the principal mechanism of thiazide-induced hyperglycemia is probably a reduction in the insulin response to glucose. Beta blockers also adversely affect blood sugar control but only by a small margin. The main cause for concern with beta blockers, however, is their effect during hypoglycemia in which nonselective agents delay blood sugar recovery. In diabetic patients, the institution of antihypertensive therapy should be followed by a reassessment to note any changes in sugar, potassium, and lipids, or side effects.
Assuntos
Anti-Hipertensivos/efeitos adversos , Glicemia/metabolismo , Diabetes Mellitus/sangue , Hipertensão/sangue , Agonistas alfa-Adrenérgicos/efeitos adversos , Antagonistas Adrenérgicos alfa/efeitos adversos , Agonistas Adrenérgicos beta/efeitos adversos , Benzotiadiazinas , Bloqueadores dos Canais de Cálcio/efeitos adversos , Diuréticos , Humanos , Hiperglicemia/induzido quimicamente , Hipertensão/tratamento farmacológico , Hipoglicemia/induzido quimicamente , Inibidores de Simportadores de Cloreto de Sódio/efeitos adversosRESUMO
The efficacy of nifedipine (N) as a "step 3" antihypertensive drug was assessed in 15 patients who remained hypertensive in spite of atenolol 100 mg and bendrofluazide 5 mg daily. Nifedipine was added in doses of 10, 20, and 30 mg three times daily in a placebo-controlled double-blind trial. Supine mean blood pressure was reduced by 11.9% +/- 6.2% by N 10 mg three times daily, by 13.9% +/- 7.6% by N 20 mg three times daily and by 20.3% +/- 6.2% by N 30 mg three times daily. Plasma potassium was reduced from 3.9 +/- 0.5 mEq/liter on placebo to 3.6 +/- 0.5 mEq/liter on N 10 mg three times daily, 3.6 +/- 0.4 mEq/liter on N 20 mg three times daily (p less than 0.05), and 3.5 +/- 0.5 mEq/liter on N 30 mg three times daily (p less than 0.05). Heart rate, body weight, renal function, and plasma glucose were not altered. Nifedipine is thus a useful third-line hypotensive agent that should be used in combination with a potassium-sparing diuretic.
Assuntos
Atenolol/administração & dosagem , Bendroflumetiazida/administração & dosagem , Hipertensão/tratamento farmacológico , Nifedipino/administração & dosagem , Propanolaminas/administração & dosagem , Piridinas/administração & dosagem , Adulto , Pressão Sanguínea/efeitos dos fármacos , Ensaios Clínicos como Assunto , Relação Dose-Resposta a Droga , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Nifedipino/efeitos adversosRESUMO
The 15-year survival of a group of 205 patients who started treatment in the period 1962 through 1966 and who received methyldopa for two-thirds or more of the time has been investigated. At entry these patients had severe hypertension with an average pretreatment pressure of 216/126 mm Hg. Twenty-one percent had retinal hemorrhages, cotton-wool spots, or papilledema. Blood pressure showed a large fall in the first year, followed by a small, progressive, further fall up to the sixth year. After 5 years of treatment the blood pressure averaged 144/90 mm Hg in men and 151/91 mm Hg in women. The average daily dose of methyldopa was approximately 1500 mg and changed little over the 15-year period. Survival was analyzed by life tables. Approximately 81% of men and women aged 30 to 49.9 years at entry were still alive 10 years later. In the age group 60 to 69.9 years, 53.8% of men and 63.2% of women were still alive 10 years later. Seventy-nine of the patients died during the follow-up period, 89% from cardiovascular or renal disease. Ischemic heart disease (40%) was the major cause of death, followed by stroke (19%). No patients died from drug toxicity.
Assuntos
Hipertensão/tratamento farmacológico , Metildopa/uso terapêutico , Adulto , Idoso , Envelhecimento , Transtornos Cerebrovasculares/mortalidade , Doença das Coronárias/mortalidade , Feminino , Seguimentos , Humanos , Hipertensão/complicações , Hipertensão/mortalidade , Nefropatias/mortalidade , Masculino , Pessoa de Meia-Idade , Neoplasias/mortalidade , Fatores Sexuais , FumarRESUMO
The British system under the Medicines Act by which new drug applications are evaluated is described in a step-by-step manner from submission of application to the issuance of a clinical trial certificate by the licensing authority. At the end of a period by clinical trials the submission is brought back for a product license. Once a drug is marketed it falls within the purview of the adverse reaction monitoring group of the Committee on Safety of Medicines (CSM). A recent innovation is "monitored release", by which, for a period of time after marketing, case reports are submitted by the pharmaceutical company to the CSM. The advantages of the British system are: (1) the final licensing decisions being made by the academic members of the Committee means that they are insulated from commercial and political pressures, and are additionally reached without undue delay; (2) academic members are not permitted to be retained as consultants to the industry on a long-term basis; (3) evaluation solely on British studies is not obligatory--foreign studies are also acceptable. Weakness in the system are: (1) recruitment of people experienced in pharmacology and therapeutics is difficult; (2) there is an inordinate work load on the academic members of the Main Committee and Subcommittees. Importance of an effective monitoring in the postmarketing stage is emphasized, because the long-term judgement must necessarily be based on wide experience in the field. The multiplication of the same of similar drugs is deplored, and innovative efforts in the quest for new drugs, especially for rare diseases, are to be encouraged.
Assuntos
Legislação de Medicamentos , Indústria Farmacêutica , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Humanos , Medicamentos sem Prescrição , Pesquisa , Reino UnidoRESUMO
The peripheral decarboxylase inhibitor carbidopa, given (100 mg/day) for 6 wk in a double-blind trial, lowered supine diastolic pressure of 10 patients with essential hypertension treated with alpha methyldopa by a small (6 mm Hg) but significant (p less than 0.05) amount. Large doses of benserazide (1.5 gm) did not modify the hypotensive effect of 1.0 gm of alpha methyldopa in untreated hypertension but significantly reduced the central nervous side effects of sedation and dry mouth. These studies indicate that extensive peripheral decarboxylation is not necessary for alpha methyldopa to lower blood pressure and would be compatible with the central nervous site of hypotensive action of this drug.
Assuntos
Carboxiliases/antagonistas & inibidores , Hemodinâmica/efeitos dos fármacos , Metildopa/farmacologia , Adulto , Benserazida/farmacologia , Benserazida/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Carbidopa/farmacologia , Carbidopa/uso terapêutico , Ensaios Clínicos como Assunto , Temperatura Baixa , Interações Medicamentosas , Quimioterapia Combinada , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Hipnóticos e Sedativos , Masculino , Metildopa/uso terapêutico , Metildopa/urina , Pessoa de Meia-Idade , Salivação/efeitos dos fármacos , Manobra de ValsalvaRESUMO
Although extensive evidence obtained in animals and in vitro supports the existence of an alpha-receptor-mediated inhibitory regulation of norepinephrine release, the importance of such a system in man is not established. Norepinephrine release was physiologically stimulated by change of posture and dynamic exercise in subjects while they were infused with phenylephrine, a predominant alpha 1-receptor agonist, alpha-methylnorepinephrine, a predominant alpha 2-agonist, and saline. Agonist infusions were administered both at rates that induced a slight elevation in supine systolic pressure and at nonpressor rates. Agonist concentrations that induced much the same pressor responses (alpha 1) were assumed on the basis of in vitro experiments to differ substantially in their affinity for alpha 2-receptors. The hemodynamic response and the increase of plasma norepinephrine induced by changes in posture and exercise were of the same order during infusions of alpha-methylnorepinephrine, phenylephrine, and saline. Similar results from the "nonpressor" as from "pressor" agonist infusions suggested that baroreflex-induced reduction in sympathetic neuronal activity had not confounded the results. Correction of plasma concentrations for individual values of norepinephrine clearance provided an index of norepinephrine release into the circulation that was not changed by phenylephrine or alpha-methylnorepinephrine. These results raise the question of the importance of peripheral alpha 2-receptors in the regulation of norepinephrine release in man.
Assuntos
Norepinefrina/metabolismo , Receptores Adrenérgicos alfa/efeitos dos fármacos , Receptores Adrenérgicos/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Nordefrin/farmacologia , Norepinefrina/sangue , Fenilefrina/farmacologia , Esforço Físico , PosturaRESUMO
Supine basal plasma norepinephrine was higher in a group of newly diagnosed patients with mild essential hypertension than in age- and sex-matched "laboratory-naive" volunteers. Sympathetic activation by exercise and change of posture increased plasma norepinephrine in both groups, with a tendency toward higher values in the hypertensive patients, but norepinephrine clearance was slower and half-life longer in these patients. Thus the estimate of neuronal norepinephrine release obtained by correction of plasma norepinephrine for individual values of clearance was in the same range in both groups. Plasma norepinephrine was lower in younger "laboratory-adapted" subjects than in the "laboratory-naive" normotensive subjects, but clearance was in the same range in both. Thus, variations in kinetics may contribute to differences in plasma norepinephrine between patients with essential hypertension and matched controls. In contrast, the lower plasma concentration of norepinephrine in "laboratory-adapted" than in "laboratory-naive" controls appears to reflect a lower level of sympathetic activity in the former.
Assuntos
Hipertensão/metabolismo , Norepinefrina/metabolismo , Adulto , Pressão Sanguínea , Meia-Vida , Frequência Cardíaca , Humanos , Cinética , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-IdadeRESUMO
A within-patient randomized, double-blind, crossover study was performed to investigate mechanisms of action of bendroflumethiazide in mild essential hypertension. Significant reductions in lying, standing, and postexercise blood pressure were seen after both 3 days and 10 wk treatment with bendroflumethiazide 10 mg daily. Plasma levels of 6-oxo-PGF1 alpha, the chemical hydrolysis product of prostacyclin, were increased by both 3 days and 10 wk therapy with bendroflumethiazide. This raises the possibility that thiazides may reduce peripheral resistance by increasing prostacyclin biosynthesis.
Assuntos
Bendroflumetiazida/farmacologia , Epoprostenol/biossíntese , Prostaglandinas/biossíntese , Adulto , Idoso , Pressão Sanguínea/efeitos dos fármacos , Eletrólitos/metabolismo , Feminino , Humanos , Hipertensão/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Norepinefrina/farmacologia , Prostaglandinas F/sangue , Renina/sangue , Sódio/metabolismoRESUMO
The activity of MK-467, a new peripherally acting alpha 2-antagonist, was assessed in volunteers by a randomized, double-blind, crossover design. One hour after administration of either 15 mg or 30 mg MK-467 or placebo, 200 micrograms clonidine was given intravenously and observations were made for a further 8 hours. Clonidine reduced plasma norepinephrine levels to 79% +/- 7% of that of control 1 hour after infusion, an effect that was antagonized by low-dose MK-467 (p less than 0.05). Mean systolic blood pressure increased by 4 mm Hg in the first hour after the 30 mg dose of MK-467 (p less than 0.01), although there was no significant difference between the 3 study days in the maximal clonidine-induced decrease in systolic pressure, diastolic pressure, or heart rate. Clonidine induced a peak increase in mean blood glucose of 13%, which was antagonized by both doses of MK-467 (p less than 0.05). Plasma insulin was suppressed by clonidine from 72 +/- 14 to 47 +/- 7 IU.L-1, an effect antagonised by both doses of MK-467 (p less than 0.05 in each case). MK-467 had no effect on clonidine-induced increased drowsiness, xerostomia, or increase in growth hormone secretion, which is consistent with it being a peripherally acting specific alpha 2-antagonist. The small effect of MK-467 on clonidine-induced changes in plasma glucose and insulin suggests that peripheral alpha 2-adrenergic receptors play only a minor role in normal glucose homeostasis.
Assuntos
Antagonistas Adrenérgicos alfa/farmacologia , Clonidina/antagonistas & inibidores , Quinolizinas/farmacologia , Administração Oral , Adulto , Glicemia/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Clonidina/farmacologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Humanos , Insulina/sangue , Masculino , Norepinefrina/sangue , Distribuição Aleatória , Salivação/efeitos dos fármacosRESUMO
The effect of atenolol, a beta adrenoceptor autogonist, on arterial pressure in patients with benign essential hypertension has been investigated. Eighteen patients were started on atenolol, 75 mg/day; the dose was increased at 2-wk intervals to a maximum of 900 mg if tolerated. When the maximum effective dose was determined, each patient was randomly allocated into a double-blind crossover study comparing atenolol and placebo treatments. The mean supine and erect arterial pressures of the 16 patients completing the run-in period were markedly reduced by atenolol therapy. The pretreatment mean (+/-SEM) supine and erect arterial pressures of the 16 patients completing the run-in period (187 +/-4.7/114 +/-2.6 and 182 +/-4.5/115 +/-3.0 mm Hg, respectively) were reduced (150 +/-5.3/97 +/-2.9 and 151 +/-5.9/100 +/-2.7 mm Hg) with atenolol therapy (p less than 0.01). In the crossover study, the mean (+/-SEM) supine arterial pressure after 8 wk of atenolol therapy in 14 patients (144 +/-5.2/89 +/-1.7 mm Hg) was lower (p less than 0.01) than at the end of placebo therapy (163 +/-4.4/105 +/-2.8 mm Hg). Similar reductions in pressure were recorded in the erect position and after exercise. No severe side effects were observed.
Assuntos
Atenolol/uso terapêutico , Hipertensão/tratamento farmacológico , Propanolaminas/uso terapêutico , Adulto , Idoso , Atenolol/sangue , Pressão Sanguínea , Ensaios Clínicos como Assunto , Feminino , Humanos , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Placebos , Renina/sangueRESUMO
The possibility that clonidine might exert some of its effects via opiate or histamine H2 receptors has been suggested from observations in animals and man. We undertook a double-blind, randomized study in six normal subjects, comparing the effects of 0.2 mg intravenous clonidine after pretreatment with 300 mg cimetidine, 0.8 mg naloxone, and saline. There was no attenuation of the hypotension, bradycardia, sedation, inhibition of salivary flow, or reduction in plasma catecholamines after cimetidine and naloxone, but the fall in plasma catecholamines ater clonidine correlated with blood pressure, sedation, and salivary flow, suggesting a central adrenergic mechanism for these effects. It is not known whether cimetidine can cross the blood-brain barrier after short-term dosing. We conclude that in normotensive subjects the short-term effects of intravenous clonidine are probably not mediated by an action at peripheral histamine H2 or central opiate receptors.
Assuntos
Clonidina/farmacologia , Receptores Histamínicos H2/efeitos dos fármacos , Receptores Histamínicos/efeitos dos fármacos , Receptores Opioides/efeitos dos fármacos , Adulto , Cimetidina/farmacologia , Epinefrina/sangue , Humanos , Masculino , Naloxona/farmacologia , Norepinefrina/sangueRESUMO
MK-912, a new alpha 2-adrenoceptor antagonist, was assessed in six volunteers by use of antagonism of the effects of intravenous clonidine as the main index of response. Subjects received single doses of either 0.2 or 2 mg of orally administered MK-912 or placebo in a randomized, double-blind, balanced, crossover design. Clonidine was infused intravenously over 10 minutes, 1 hour after dosing, and observations were made for 8 hours. The 2 mg dose of MK-912 significantly inhibited the clonidine-induced hypotension, bradycardia, xerostomia, and increase in plasma glucose concentrations that were observed during the placebo treatment period (p less than 0.05). The peak elevation in plasma growth hormone that was produced by clonidine on the day the placebo was given was inhibited an average of 87% by the 2 mg dose of MK-912 (p less than 0.01). Although there was a trend toward antagonism of clonidine by the 0.2 mg dose of MK-912, statistically significant differences from placebo were not consistently demonstrated for most parameters. However, a mean 59% inhibition of the clonidine-induced peak elevation of plasma growth hormone was observed (p less than 0.05). Oral MK-912 almost completely inhibits the effect of 200 micrograms of intravenous clonidine in human subjects, which is consistent with its role as a potent alpha 2-antagonist over the dose range of 0.2 to 2.0 mg.
Assuntos
Antagonistas Adrenérgicos alfa/farmacologia , Clonidina/antagonistas & inibidores , Quinolizinas/farmacologia , Adulto , Glicemia , Pressão Sanguínea/efeitos dos fármacos , Clonidina/administração & dosagem , Método Duplo-Cego , Gonadotropinas/sangue , Frequência Cardíaca/efeitos dos fármacos , Humanos , Infusões Intravenosas , Masculino , Distribuição Aleatória , Salivação/efeitos dos fármacosRESUMO
Saliva half-life of antipyrine was studied in 49 healthy Gambians between 20 and 60 yr of age of whom 27 were male (mean age, 44.5) and 22 female (mean age, 39.1). Body wieght, height, ponderal index, albumin, and hemoglobin were moderately reduced compared to accepted normal values. Antipyrine half-life was 13.6 +/- 0.58 (SEM) hr. Multiple regression analysis showed that sex, cola nut consumption, hemoglobin in women, and height in men were statiscally significant independent predictors of antipyrine half-life. Half-life was shorter in women, decreased with an increase in height in men, and was prolonged by cola nut consumption. Half-life in women increased with hemoglobin. These factors explained 36% of the variation and suggest that geographic differences in the environment could be important in drug metabolism in man.
Assuntos
Antipirina/metabolismo , Adulto , Fatores Etários , Dieta , Feminino , Gâmbia , Meia-Vida , Hemoglobinas/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Nozes , Saliva/metabolismo , Fatores SexuaisRESUMO
It is possible to predict plasma concentrations of drugs by measurement in saliva, obviating the need for venipuncture. Using a selection of weakly acidic and basic drugs, we have found this prediction reliable for drugs largely nonionized at normal plasma pH (phenytoin, phenobarbital, antipyrine) but unreliable for ionized drugs (chlorpropramide, tolbutamide, propranolol, meperidine). Deliberate alteration of saliva flow rate and pH using different stimuli have produced twofold changes in saliva drug concentrations. Wide interindividual variability of saliva pH is the likely explanation for the inconstancy of saliva to plasma concentration ratios for ionized drugs.
Assuntos
Preparações Farmacêuticas/metabolismo , Saliva/análise , Adolescente , Adulto , Idoso , Antipirina/metabolismo , Clorpropamida/metabolismo , Humanos , Concentração de Íons de Hidrogênio , Masculino , Meperidina/metabolismo , Pessoa de Meia-Idade , Preparações Farmacêuticas/sangue , Fenobarbital/metabolismo , Fenitoína/metabolismo , Propranolol/metabolismo , Ligação Proteica , Tolbutamida/metabolismoRESUMO
Cardiovascular effects of 1-butyl-3(1-(6,7-dimethoxyquinazolin-4-yl) piperidin 4 yl urea) (BDPU) were studied in 16 anesthetized dogs and in 7 healthy male volunteers. In animal experiments intravenous doses of 100, 250, and 500 mug/kg/min produced dose-related, significant increases in cardiac output and peak left ventricular dp/dt. No changes in heart rate and blood pressure occurred at 100 mug/kg/min, whereas higher doses caused falls in both systolic and diastolic blood pressures, accompanied by significant rises in heart rate. Inotropic effects could also be demonstrated in man. Changes of the systolic time intervals were dose-related and began at 64 mug/kg/min. At 250 mug/kg/min, the highest dose administered, the pre-ejection period decreased by 14.8 +/- 4.42 msec and its ratio with left ventricular ejection time by 0.049 +/- 0.017 against their respective control values (p less than 0.01). In contrast to animal experiments, no hypotension or tachycardia was observed in any subject. Pharmacokinetic studies showed a plasma elimination half-life of 76 +/- 3 min (mean +/- SE). There were no subjective side effects and standard laboratory tests were not altered, but there was a slight but significant rise in the urinary enzymes, lactic dehydrogenase (LDH) and glutamic oxaloacetic transaminase (GOT), which persisted up to 7 days.